Donald A Berry

Donald A Berry

UNVERIFIED PROFILE

Are you Donald A Berry?   Register this Author

Register author
Donald A Berry

Donald A Berry

Publications by authors named "Donald A Berry"

Are you Donald A Berry?   Register this Author

100Publications

3084Reads

19Profile Views

Concern Regarding Age Distribution of Breast Cancer.

JAMA Surg 2018 Nov;153(11):1060-1061

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamasurg.2018.2087DOI Listing
November 2018

Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.

JAMA 2018 06;319(22):2336

Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.4261DOI Listing
June 2018

A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality.

Med Decis Making 2018 04 19;38(1_suppl):78S-88S. Epub 2017 Jun 19.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X17714473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711634PMC
April 2018

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Med Decis Making 2018 04;38(1_suppl):3S-8S

Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X17737507DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862043PMC
April 2018

Distinguishing between CISNET model results versus CISNET models.

Cancer 2018 03 26;124(5):1083-1084. Epub 2017 Dec 26.

Carbone Cancer Center, Department of Population Health Science, School of Medicine and Public Health, University of Wisconsin at Madison, Madison, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31150DOI Listing
March 2018

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply.

Authors:
Donald A Berry

JAMA Oncol 2017 03;3(3):416-417

Berry Consultants, LLC, Austin, Texas2Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3947DOI Listing
March 2017

Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.

Alzheimer Dis Assoc Disord 2015 Jul-Sep;29(3):192-9

*AbbVie Inc., North Chicago, IL †Berry Consultants, LLC, Austin, TX ‡MD Anderson Cancer Center, University of Texas, Houston, TX §Division of Neurology, Nova Southeastern University, Fort Lauderdale, FL ∥Palm Beach Neurology, West Palm Beach, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WAD.0000000000000093DOI Listing
August 2016

Adaptive Randomization of Neratinib in Early Breast Cancer.

N Engl J Med 2016 Jul;375(1):11-22

From University of California, San Francisco (J.W.P., C.Y., L.J.V., N.M.H., M.B.B., A.J.C., M.M., J.L., S.E.D., G.L.H., L.J.E.), and QuantumLeap Healthcare Collaborative (M.P.), San Francisco, Buck Institute for Research and Aging, Novato (C.Y.), University of California, Davis, Davis (M.H.), University of California, San Diego, San Diego (A.M.W., R.S., T.H.), and University of Southern California, Los Angeles (D.T.) - all in California; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.C.L., C.I.); University of Minnesota, Minneapolis (D.Y., T.C.H.), and Mayo Clinic, Rochester (J.C.B.) - both in Minnesota; M.D. Anderson Cancer Center, Houston (W.F.S., L.P., S.L.M., D.A.B.), University of Texas Southwestern Medical Center, Dallas (D.M.E., B.B.H.), and Berry Consultants, Austin (A.S., D.A.B.) - all in Texas; Gemini Group, Ann Arbor, MI (J.P.); University of Pennsylvania, Philadelphia (A.D.); Oregon Health and Sciences University, Portland (S.Y.C., K.A.K.); Swedish Medical Center, Seattle (H.G.K.); University of Chicago (R.N.) and Loyola University (K.S.A.) - both in Chicago; Inova Fairfax Hospital, Falls Church, VA (K.K.E.); University of Denver, Denver (A.D.E.); Mayo Clinic, Scottsdale (D.W.N.), and University of Arizona, Tucson (J.E.L., R.K.V.) - both in Arizona; University of Kansas, Lawrence (Q.J.K.); and Emory University, Atlanta (W.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558PMC
July 2016

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

N Engl J Med 2016 Jul;375(1):23-34

From University of California, San Francisco (UCSF) (H.S.R., C.Y., L.J.V., M.B.B., N.M.H., A.J.C., C.E., J.L., S.E.D., G.L.H., L.J.E.), and QuantumLeap Healthcare Collaborative (M.P.), San Francisco, Buck Institute for Research and Aging, Novato (C.Y.), University of California, Davis, Davis (M.H.), University of California San Diego, San Diego (A.M.W., R.S.), and University of Southern California, Los Angeles (D.T.) - all in California; University of Chicago (O.I.O., R.N.), and Loyola University (K.S.A.), Chicago; University of Pennsylvania, Philadelphia (A.D.); Gemini Group, Ann Arbor, MI (J.P.); University of Texas M.D. Anderson Cancer Center, Houston (W.F.S., L.P., S.L.M., D.A.B.), UT Southwestern Medical Center, Dallas (D.M.E., B.B.H.), and Berry Consultants, Austin (A.S., D.A.B.) - all in Texas; University of Minnesota, Minneapolis (D.Y.), and Mayo Clinic, Rochester (J.C.B., T.C.H.) - both in Minnesota; Swedish Medical Center, Seattle (H.G.K.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.C.L., C.I.); University of Kansas, Lawrence (Q.J.K.); University of Arizona, Tucson (J.E.L., R.K.V.), and Mayo Clinic, Scottsdale (D.W.N.) - both in Arizona; Oregon Health and Sciences University, Portland (S.Y.C., K.A.K.); University of Denver, Denver (A.D.E.); Inova Fairfax Hospital, Falls Church, VA (K.K.E.); and Emory University, Atlanta (W.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259561PMC
July 2016

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

J Clin Oncol 2016 Feb 2;34(6):542-9. Epub 2015 Nov 2.

Lisa A. Carey, David W. Ollila, Carey K. Anders, Katherine A. Hoadley, Michael Iglesia, and Charles M. Perou, University of North Carolina Chapel Hill, Chapel Hill; Constance T. Cirrincione and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Donald A. Berry, Alliance Statistics and Data Center, MD Anderson, Houston, TX; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Ian E. Krop and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Lyndsay N. Harris, University Hospitals of Cleveland, Cleveland, OH; Norah Lynn Henry, University of Michigan, Ann Arbor, MI; Douglas J. Weckstein, New Hampshire Hematology-Oncology, Hooksett, NH; Baljit Singh, New York University; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; and Maggie Chon U. Cheang, Clinical Trials and Statistics Unit, Institute of Cancer Research, Belmont, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567PMC
February 2016

Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer.

Authors:
Donald A Berry

Clin Cancer Res 2016 Jan 28;22(1):3-5. Epub 2015 Oct 28.

Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703523PMC
January 2016

From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

J Clin Oncol 2015 Nov 24;33(31):3583-90. Epub 2015 Aug 24.

Kanwal Pratap Singh Raghav, Sminil Mahajan, James C. Yao, Brian P. Hobbs, Donald A. Berry, Alda Tam, Waun K. Hong, Lee M. Ellis, and Michael J. Overman, The University of Texas MD Anderson Cancer Center, Houston, TX; Rebecca D. Pentz, Emory School of Medicine, Atlanta, GA; and James Abbruzzese, Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.4148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979242PMC
November 2015

CNS Anticancer Drug Discovery and Development Conference White Paper.

Neuro Oncol 2015 Nov;17 Suppl 6:vi1-26

Kaiser Permanente, Redwood City, California, USA (V.A.L.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (V.A.L.); University of California, San Francisco, CA, USA (V.A.L.); SUNY Stony Brook University, Stony Brook, NY, USA (P.J.T.); Icahn School of Medicine at Mount Sinai, New York, NY, USA (J.M.G., M.R.B., A.C.D.); Columbia University Institute for Cancer Genetics, New York, NY, USA (A.I.); Fred Hutchinson Cancer Research Center, Seattle, WA, USA (P.J.P.); Genentech, Inc., South San Francisco, CA, USA (T.P.H.); University of Minnesota School of Pharmacy, Minneapolis, MN, USA (W.F.E.); Angiochem, Inc., Montreal, Quebec, Canada (J.E.L.); Pfizer Oncology, San Diego, CA, USA (T.W.J.); Massachusetts Institute of Technology, Cambridge, MA, USA (F.M.W.); US Food and Drug Administration, Silver Spring, MD, USA (J.S.); Texas Tech University School of Pharmacy, Amarillo, TX, USA (Q.R.S., R.S.); NewGen Therapeutics, Inc., Menlo Park, CA, USA (W.S.); Mayo Clinic, Rochester, MN, USA (J.N.S.); Dana-Farber Cancer Institute, Boston, MA, USA (P.Y.W.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (D.A.B.); Celgene Avilomics Research, Bedford, MA, USA (R.C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581696PMC
November 2015

Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval.

JAMA Oncol 2015 Oct;1(7):875-6

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.1293DOI Listing
October 2015

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Ann Surg 2015 Sep;262(3):434-9; discussion 438-9

*Department of Surgery, Brigham and Women's Hospital, Boston, MA †Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC ‡Department of Medical Oncology Women and Infants Hospital and Alpert Medical School of Brown University, Providence, RI §Alliance Statistics and Data Center, MD Anderson Cancer Center, Houston, TX ¶Department of Medical Oncology, Maine Center for Cancer Medicine, Scarborough, ME ∥Department of Medical Oncology, City of Hope Medical Center, Los Angeles, CA **Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY ††Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and ‡‡Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000001417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710511PMC
September 2015

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Neuro Oncol 2015 Aug 7;17(8):1106-13. Epub 2015 Jan 7.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (L.T., G.P.); Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts (L.T., G.P.); Center for Neuro-Oncology Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, (P.Y.W., B.M.A.); Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (B.M.A.); Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (D.A.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490868PMC
August 2015

The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.

Authors:
Donald A Berry

Mol Oncol 2015 May 11;9(5):951-9. Epub 2015 Mar 11.

Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2010, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.02.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516171PMC
May 2015

Commentary on Hey and Kimmelman.

Authors:
Donald A Berry

Clin Trials 2015 Apr 3;12(2):107-9. Epub 2015 Feb 3.

Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774515569011DOI Listing
April 2015

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Neuro Oncol 2015 Feb 26;17(2):180-8. Epub 2014 Aug 26.

Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (B.M.A., L.T., K.L.L., P.Y.W.); Mayo Clinic, Rochester, Minnesota (E.G., K.V.B., B.P.O., J.N.S.); The University of Texas M.D. Anderson Cancer Center, Houston, Texas (W.K.A.Y., J.F.D., D.A.B.); St. Jude Children's Research Hospital, Memphis, Tennessee (J.M.B.); University of California, Los Angeles, California (T.F.C.); Memorial Sloan-Kettering Cancer Center, New York, New York (J.T.H., I.K.M.); National Cancer Institute, Bethesda, Maryland (B.M., A.T.-A.); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (W.M.); Henry Ford Hospital, Detroit, Michigan (T.M.); University of California, San Diego, La Jolla, California (P.S.M.); University of California, San Francisco, California (M.D.P.); Johns Hopkins University, Baltimore, Maryland (X.Y.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288520PMC
February 2015

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

J Clin Oncol 2015 Jan 4;33(1):13-21. Epub 2014 Aug 4.

William M. Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI; Donald A. Berry, University of Texas MD Anderson Cancer Center, Houston, TX; Charles M. Perou and Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Constance T. Cirrincione, Alliance Statistical Center, Durham; Charles S. Kuzma, Southeast Cancer Control Consortium, Winston-Salem, NC; Baljit Singh, New York University Medical Center; Elisa R. Port, Mount Sinai Medical Center; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Sara M. Tolaney, Mehra Golshan, Jennifer R. Bellon, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Timothy J. Pluard, Washington University-St Louis Medical Center, St Louis, MO; George Somlo, City of Hope Comprehensive Cancer Center, Duarte; Deborah Collyar, Patient Advocates in Research, Danville, CA; and Olwen M. Hahn, University of Chicago Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268249PMC
January 2015

Reply to V. Amoroso et al.

J Clin Oncol 2015 Jan 15;33(3):291. Epub 2014 Dec 15.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.1875DOI Listing
January 2015

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

J Natl Cancer Inst 2014 Nov 24;106(11). Epub 2014 Sep 24.

Division of Biomedical Informatics Research (DM) and Department of Radiology (DM, SKP), School of Medicine, Stanford University, Stanford, CA (DM); Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC (AMN, YC, JSM); Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands (NTvR, HJdK, EAMH); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School Boston, MA (SJL, HH); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York (CBS); Department of Industrial and Systems Engineering, University of Wisconsin, Madison, WI (OA, MAE); Carbone Cancer Center, University of Wisconsin, Madison, WI (ESB, ATD); University of Texas M.D. Anderson Cancer Center, Houston, TX (DAB, GC); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Department of Surgery, College of Medicine, University of Vermont, VT (BLS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271026PMC
November 2014

Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: application to an article in Cancer.

Authors:
Donald A Berry

Cancer 2014 Sep 12;120(18):2784-91. Epub 2014 Jun 12.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28795DOI Listing
September 2014

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

J Clin Oncol 2014 Aug 16;32(22):2311-7. Epub 2014 Jun 16.

Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484PMC
August 2014

Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Epidemiol Rev 2014 ;36:114-36

Abbreviations: CI, confidence interval; ER, estrogen receptor; MeSH, Medical Subject Headings; PR, progesterone receptor; RR, risk ratio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/epirev/mxt010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873844PMC
June 2014

Response.

Authors:
Donald A Berry

J Natl Cancer Inst 2014 Apr 3;106(5). Epub 2014 Apr 3.

Affiliations of authors: Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju065DOI Listing
April 2014

Predicting clinical trial results based on announcements of interim analyses.

Trials 2014 Mar 7;15:73. Epub 2014 Mar 7.

Berry Consultants, LLC, 4301 Westbank Dr, Suite 140, Bldg B, Austin, TX 78746, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1745-6215-15-73DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973959PMC
March 2014

Response.

Authors:
Donald A Berry

J Natl Cancer Inst 2014 Feb 9;106(2):djt380. Epub 2014 Jan 9.

Affiliation of author: Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt380DOI Listing
February 2014

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.

Neuro Oncol 2013 Aug 14;15(8):972-8. Epub 2013 Jul 14.

Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/not088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714161PMC
August 2013

Breast cancer screening: controversy of impact.

Authors:
Donald A Berry

Breast 2013 Aug;22 Suppl 2:S73-6

Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler Street, 4-5062 Pickens Academic Tower, Houston, TX 77030-1402, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.07.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192714PMC
August 2013

Meta-analyses of colorectal cancer risk factors.

Cancer Causes Control 2013 Jun 6;24(6):1207-22. Epub 2013 Apr 6.

School of Nursing and Community and Family Medicine, Duke University, 307 Trent Drive, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-013-0201-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161278PMC
June 2013

From drug discovery to biomarker-driven clinical trials in lymphoma.

Nat Rev Clin Oncol 2012 Nov 11;9(11):643-53. Epub 2012 Sep 11.

Department of Lymphoma/Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5206990PMC
November 2012

Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.

Clin Cancer Res 2012 Nov 26;18(22):6356-63. Epub 2012 Sep 26.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0178DOI Listing
November 2012

Adaptive clinical trials: a partial remedy for the therapeutic misconception?

JAMA 2012 Jun;307(22):2377-8

Department of Emergency Medicine, University of Michigan, Ann Arbor, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2012.4174DOI Listing
June 2012

Bayesian approaches for comparative effectiveness research.

Authors:
Donald A Berry

Clin Trials 2012 Feb 30;9(1):37-47. Epub 2011 Aug 30.

Department of Biostatistics - 1409, The University of Texas MD Anderson Cancer Center, Houston, TX 77230–1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774511417470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314707PMC
February 2012

Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.

Clin Cancer Res 2012 Feb;18(3):638-44

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314693PMC
February 2012

Adaptive clinical trials in oncology.

Authors:
Donald A Berry

Nat Rev Clin Oncol 2011 Nov 8;9(4):199-207. Epub 2011 Nov 8.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, 4-5062 Pickens Academic Tower, Houston, TX 77030-1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.165DOI Listing
November 2011

Modeling the impact of population screening on breast cancer mortality in the United States.

Breast 2011 Oct;20 Suppl 3:S75-81

Department of Oncology and Medicine, Georgetown University Medical Center and Cancer Control Program, Lombardi Comprehensive Cancer Center, 3300 Whitehaven St, NW, Suite 4100, Washington, DC 20007, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0960-9776(11)70299-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457919PMC
October 2011

Computer-assisted detection and screening mammography: where's the beef?

Authors:
Donald A Berry

J Natl Cancer Inst 2011 Aug 27;103(15):1139-41. Epub 2011 Jul 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr267DOI Listing
August 2011

Next generation clinical trials.

Authors:
Donald A Berry

Clin Adv Hematol Oncol 2011 Aug;9(8):601-3

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
August 2011

FDA recalls not as alarming as they seem.

Arch Intern Med 2011 Jun;171(11):1044-5; author reply 1045-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archinternmed.2011.242DOI Listing
June 2011

Adaptive clinical trials: the promise and the caution.

Authors:
Donald A Berry

J Clin Oncol 2011 Feb 20;29(6):606-9. Epub 2010 Dec 20.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.32.2685DOI Listing
February 2011

The hazards of endpoints.

Authors:
Donald A Berry

J Natl Cancer Inst 2010 Sep 8;102(18):1376-7. Epub 2010 Sep 8.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djq334DOI Listing
September 2010

Bayesian meta-analyses for comparative effectiveness and informing coverage decisions.

Med Care 2010 Jun;48(6 Suppl):S137-44

Berry Consultants, College Station, TX 77845, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MLR.0b013e3181e24563DOI Listing
June 2010

Detecting an overall survival benefit that is derived from progression-free survival.

J Natl Cancer Inst 2009 Dec 9;101(23):1642-9. Epub 2009 Nov 9.

Department of Statistics, Texas A&M University, College Station, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djp369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137232PMC
December 2009

Adjuvant chemotherapy for breast cancer in older women.

Authors:
Donald A Berry

Womens Health (Lond) 2009 Sep;5(5):453-7

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/full/10.2217/WHE.09.46
Publisher Site
http://dx.doi.org/10.2217/whe.09.46DOI Listing
September 2009

Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.

Clin Trials 2009 Jun;6(3):205-16

Department of Biostatistics, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774509104992DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913209PMC
June 2009